Optic Neuritis- Pipeline Insight, 2024

Optic Neuritis- Pipeline Insight, 2024

DelveInsight’s, “Optic Neuritis- Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Optic Neuritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Optic Neuritis: Understanding

Optic Neuritis: Overview

Optic neuritis is an inflammatory condition that affects the optic nerve, the crucial pathway for transmitting visual information from the eye to the brain. This inflammation disrupts normal nerve function, leading to symptoms such as sudden vision loss, pain with eye movement, color vision deficiency, and sometimes seeing flashing lights. The vision loss typically affects one eye, although both eyes can be involved in some cases. The associated pain, often exacerbated by eye movement, is a distinguishing feature of optic neuritis.

The causes of optic neuritis are varied, with autoimmune disorders being the most common. Conditions like multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) are frequently associated with optic neuritis. Infections, such as those caused by viruses like measles, mumps, and herpes, can also trigger the condition. Rarely, vaccinations and other autoimmune diseases like lupus and sarcoidosis may involve the optic nerve, leading to optic neuritis.

Diagnosing optic neuritis involves a comprehensive clinical evaluation. Physicians assess symptoms and conduct a thorough ophthalmologic examination. Tests include visual acuity measurement, pupil response evaluation, and ophthalmoscopy to check for optic disc swelling. Magnetic resonance imaging (MRI) is often used to identify inflammation of the optic nerve and to rule out other conditions, such as MS. Blood tests may be conducted to detect antibodies associated with NMOSD or other underlying autoimmune conditions.

Treatment for optic neuritis aims to reduce inflammation and manage symptoms. Corticosteroids are typically the first line of treatment, administered either intravenously or orally, to speed up recovery. In severe cases or when steroids are ineffective, plasma exchange (plasmapheresis) may be used. For patients with recurrent optic neuritis, particularly those with MS or NMOSD, long-term immunomodulatory therapy may be necessary. Symptomatic management, including pain relief and supportive care for vision loss, is also important.

The prognosis for optic neuritis varies. Many patients experience significant improvement in vision within a few weeks to months, although some may have residual deficits. Recurrent episodes, especially in those with associated autoimmune conditions, can lead to cumulative damage and a higher risk of permanent vision loss. Therefore, prompt diagnosis and treatment are essential to minimize long-term visual impairment and to manage underlying conditions effectively.

""Optic Neuritis- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Optic Neuritis pipeline landscape is provided which includes the disease overview and Optic Neuritis treatment guidelines. The assessment part of the report embraces, in depth Optic Neuritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Optic Neuritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Optic Neuritis R&D. The therapies under development are focused on novel approaches to treat/improve Optic Neuritis.

Optic Neuritis Emerging Drugs Chapters

This segment of the Optic Neuritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Optic Neuritis Emerging Drugs

OCS-05: Oculis

OCS-05 has a novel mechanism of action (MoA) which activates Serum-Glucocorticoid Kinase-2 (SGK-2). It is hypothesized that SGK-2 is part of the neurotrophic factor signaling pathways, to support neuronal cell development, survival, and repair, including oligodendrocyte precursor differentiation and myelination. SGK-2 activation leads to: an upregulation of signaling molecules forkhead box O3 (FOXO3); which reduces apoptosis, the downregulation of glycogen synthase kinase 3 beta (GSK3B), which improves anti-oxidation; and an upregulation of N-myc downstream-regulated gene 1 (NDRG1) involved in oligodendrocyte development and differentiation. Disease modulating activity of OCS-05 may distinguish it as a potential treatment for ophthalmic diseases involving neurological damage. Pre-clinical studies suggest that OCS-05 is neuroprotective and has remyelinating activity.

A European Phase I clinical trial (with 48 healthy volunteers) showed that OCS-05 was well tolerated with good pharmacokinetics (PK) correlation with its pre-clinical animal studies. The results of these studies has enabled the advancement of OCS-05 into a First-in-Patient clinical proof-of-concept trial. The Acute OptiC NeUrITis of DemYelinating Origin (ACUITY) trial, a randomized, double-masked, placebo controlled, multiple center trial, is enrolling patients diagnosed with AON. Currently, the drug is in Phase II stage of its development for the treatment of Optic Neuritis.

Further product details are provided in the report……..

Optic Neuritis: Therapeutic Assessment

This segment of the report provides insights about the different Optic Neuritis drugs segregated based on following parameters that define the scope of the report, such as:

MajorPlayers in Optic Neuritis

There are approx. 4+ key companies which are developing the therapies for Optic Neuritis. The companies which have their Optic Neuritis drug candidates in the most advanced stage, i.e. Phase II include, Oculis.

Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Optic Neuritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Optic Neuritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Optic Neuritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Optic Neuritis drugs.

Optic Neuritis Report Insights

Optic Neuritis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Optic Neuritis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Optic Neuritis drugs?

How many Optic Neuritis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Optic Neuritis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Optic Neuritis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Optic Neuritis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Oculis

Find Therapeutics

Key Products

OCS-05

FTX101